Lineage Cell Therapeutics Inc (LCTX)vsMerck & Company Inc (MRK)
LCTX
Lineage Cell Therapeutics Inc
$1.43
-2.05%
HEALTHCARE · Cap: $363.98M
MRK
Merck & Company Inc
$113.56
+0.36%
HEALTHCARE · Cap: $277.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 451727% more annual revenue ($65.77B vs $14.56M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK appears more attractively valued with a PEG of 3.43. MRK earns a higher WallStSmart Score of 53/100 (C-).
LCTX
Avoid29
out of 100
Grade: F
MRK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.7%
Fair Value
$13.55
Current Price
$1.43
$12.12 discount
Margin of Safety
-15.7%
Fair Value
$97.76
Current Price
$113.56
$15.80 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 130.4% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 38.1%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LCTX
The strongest argument for LCTX centers on Revenue Growth, Debt/Equity. Revenue growth of 130.4% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.
Bear Case : LCTX
The primary concerns for LCTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
LCTX profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
LCTX carries more volatility with a beta of 1.60 — expect wider price swings.
LCTX is growing revenue faster at 130.4% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (53/100 vs 29/100). LCTX offers better value entry with a 86.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage Cell Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?